TickerTalks
Browse all tickers →
TickerTalks›$OPRX
OPOPRX

OptimizeRx Corp.

$OPRX·$165M·Medical - Healthcare Information Services·Healthcare
$8.23-2.9%1Y-51.5%
Mentions · last 7 days
2026-08-11: 3 posts2026-08-12: 9 posts2026-08-13: 8 posts2026-08-14: 8 posts2026-08-15: 1 posts2026-08-16: 0 posts2026-08-17: 0 posts290%
Price updated 5h ago·X counts updated 1d ago
OPOPRX
$OPRXOptimizeRx Corp.
$8.23-2.95%29 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $OPRX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storyWinding up for a moveAI verdict · as of 2026-08-15

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

OptimizeRx is the EHR pharma-messaging -50% t12m — Q2 EPS beat +44%, but revenue -30% YoY, 4 straight beats, Dimensional bought 102K shares.

OptimizeRx is a digital-health company (EHR-based pharmaceutical messaging + financial messaging + patient education for healthcare providers) — the equity is a broken-story name coiling on the specific 4-beat pattern despite the persistent revenue decline.

  • Q2 was a big beat: EPS $0.16 vs $0.111 (+44%), revenue $20.5M vs $20.2M (+1%) — the specific fact pattern of margin execution despite topline weakness.
  • 4 consecutive massive beats: Q2 +44%, Q1 +1300%, Q4 +122%, Q3 +567% — real beats vs low-base consensus.
  • BUT revenue declining: Q2 -30% YoY, Q1 -10% YoY — real underlying demand-weakness.
  • Position at 24% of 52w with stock +43% above 50d MA and -4% below 200d MA — coiled tape mid-range drawdown, t12m -50%.
  • Fundamentals: 72% GM, 11% OM, 5% ROIC, 4% ROE, 11% FCF yield at $165M mc, 36x TTM P/E — recovery-stage margins.
  • Analyst EPS $0.94 FY26 → $1.09 FY27 with revenue $97M → $109M — modest recovery trajectory.
  • Volume multiplier 1.4x average — real accumulation flow.
  • Dimensional Fund Advisors purchased 102,661 shares (8/13) — real institutional accumulation.
  • 'OptimizeRx Announces Finance Leadership Appointments' (8/12) — real specific team-building event.

Next dated events not disclosed — a fifth beat with revenue stabilization commentary extends the coiled run; another revenue-decline cements broken-story. The real risk on -50% t12m with -30% rev decline is that pharmaceutical-marketing spend cuts persist regardless of margin recovery.

What to watch: Next quarterly print — revenue trajectory and any pharma-marketing recovery commentary. A fifth beat with rev stabilization extends the coil; another decline cements broken-story.

no sentiment

Read the AI verdict + X sentiment for $OPRX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Information Services sits in its cycle right now — and what that implies for $OPRX.

Medical - Healthcare Information Services · Healthcare

No material change from last week — VEEV's 'agentic commercial' CRM framing converts AI from feature to platform pricing, while TEM's oncology AI platform and pharma data licensing confirm AI..

Industry benchmark

11-name peer basket
+30.0%YTD
+30.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
36.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
4.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
11.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
11.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
3.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
72.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$0.16$0.11+44.0%
Q1 2026May 12, 2026$0.14$0.01+1300.0%
Q4 2025Mar 5, 2026$0.51$0.23+121.7%
Q3 2025Nov 6, 2025$0.20$0.03+566.7%
Next earningsThu, Nov 5·consensus EPS $0.24

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$20.5M-29.8%76.5%-0.4%$-0.04$8.6M
Q1 FY26$19.8M-9.5%69.9%2.0%$-0.03$-488K
Q4 FY25$32.2M-0.2%74.8%27.7%$0.27$7.1M
Q3 FY25$26.1M+22.3%67.2%7.9%$0.04$3.2M

Forward consensus

2-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$97.4M$97.0M – $98.1M$0.94$0.91 – $0.955
FY27$108.9M$101.7M – $117.1M$1.09$0.98 – $1.245

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.21%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+32.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-8.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 14.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.055-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 9 other (7 awards · 2 inkinds) in window

See when $OPRX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeAug 128-K — Item 2.02: Earnings release · Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

OptimizeRx Corporation reported Q2 2026 financial results and announced a planned CFO succession: Edward Stelmakh will step down as Chief Financial and Strategy Officer on December 31, 2026, with Andrew D'Silva taking over as CFO and Heather Favazza becoming Chief Accounting Officer on January 1, 2027. Stelmakh's separation package includes 12 months of salary continuation at his $450,000 annual rate, a $247,500 lump-sum bonus, and COBRA reimbursement. OptimizeRx operates a digital health platform connecting pharmaceutical companies with healthcare providers. The orderly transition plan provides over five months of overlap.

8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
8-KOfficer or director changeJun 58-K — Item 5.02: Officer or director change
8-KAgreement terminatedMay 128-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.02: Earnings release · Item 2.03: Material debt obligation
3New insider — initial holdingsApr 223
8-KOfficer or director changeApr 98-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-KMaterial eventMar 308-K — Item 4.01
8-KMaterial agreementMar 58-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 8.01: Other event
+ 10 other (4 13Gs · 2 10-Qs · 2 proxys · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Dimensional Fund Advisors LP Purchases 102,661 Shares of OptimizeRx Corp. $OPRXdefenseworld.net·6d agoOptimizeRx Q2 Earnings Call Highlightsmarketbeat.com·6d agoOptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcriptseekingalpha.com·6d agoOptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimateszacks.com·6d agoOptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growthglobenewswire.com·6d ago

More in Medical - Healthcare Information Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$HTFL$TEM$DOCS$TXG$GEHC$HNGE$WGS$TDOC
Voices on X · last 7 days

No standout posts about $OPRX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport